Background: HIV-1 cell-cell transmission promotes high efficacy of infection, which inflicts a dramatic loss in neutralization potency even by broadly neutralizing antibodies (bnAbs) compared to free virus infection. A precise definition of inhibitory potentials during cell-cell transmission is therefore needed to select bnAbs that are capable of suppressing HIV irrespective of the transmission mode, securing in vivo activity and allowing for their use as vaccines and in passive immunization.
Methods: We have compiled assay systems that allow for unambiguous discrimination between free virus and cell-cell transmission. For this, PBMC or CD4+ CCR5+ A3.01 T cells were co-cultured with producer cells (PBMC or 293-T cells), either infected with replication competent virus or transfected with env pseudotyped inGLuc reporter viruses to distinguish cell-cell transmission from fusion events. Inhibitory capacities of the bnAbs (b12, VRC01, NIH45-46, 3BNC117, PGV04, PGTs 121, 125, 128, 135, 145, PG9, PG16, 2G12, 10E8, 2F5, 4E10) during cell-cell transmission of HIV-1 strains from subtypes A, B and C were studied and their potency to block virus transmission pre and post CD4 engagement was assessed.
Results: Across almost all bnAb-virus combinations tested, the potency to inhibit HIV-1 cell-cell transmission was strongly decreased compared to free virus transmission. However, loss of potency varied considerably between virus strains and strikingly, high potency against free virus did not ensure lower loss in activity during cell-cell transmission. In rare bnAb-virus combinations, inhibition capacities proved comparable for both transmission modes but no bnAb that potently blocked cell-cell transmission over a range of HIV-1 strains could be identified. Likewise, the capacity of bnAbs to block HIV infection post CD4 engagement differed among virus strains and bnAbs tested.
Importantly, mathematical analysis employed to estimate the consequences of the observed activity loss during cell-cell transmission indicated an increased probability of viral resistance mutations to arise in cell-cell rather than free virus spread.
Conclusions: Our data suggest that the efficacy of bnAbs during cell-cell transmission cannot be predicted by their free virus activity and greatly differs in a strain-dependent manner. Potent inhibition of both transmission routes will only be possible through a combination of bnAbs, either by multi-component vaccines or antibody cocktails in passive immunization.